Erectile Dysfunction News
-
How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
-
Futura agrees to licensing deal to commercialize ED product in UK & Europe
Futura Medical plc has signed an exclusive licensing agreement with over the counter (OTC) distributor Cooper Consumer Health SAS to commercialize its topical, gel-based erectile dysfunction (ED) treatment Med3000, in the U.K. and Europe. Under the terms of the agreement, Cooper will pay an undisclosed price to Futura to manufacture and supply the product for five years, in compliance with EU ...
-
Research Suggests COVID-19 Affects Erectile Function
"One of the repercussions of COVID-19 is its impact on men's sexual health. COVID-19 infection is expected to be associated with an increased likelihood of erectile dysfunction (ED). Considering the high transmissibility of COVID-19, ED could be a concerning consequence for a large segment of the population" https://www.ncbi.nim.nih.gov/pmc/articles/PMC8450276/. Coincidentally, DirexGroup ...
By DirexGroup
-
Creative Medical Technology to Showcase CaverStem at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology and orthopedics, today announced that it will be exhibiting at the American Urological Association ("AUA") Annual Meeting on May 13-16, 2022 in New Orleans to showcase ...
-
Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical`s Marrow Cellution Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction
Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has signed an agreement with Cervos Inc. ("Cervos Medical") to become the exclusive distributor of Marrow Cellution™ ...
-
Profound Medical Announces First Patients Treated in Prospective, Randomized Clinical Trial Comparing the TULSA Procedure to Radical Prostatectomy
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that the first patients have been treated in the Level 1 ‘CAPTAIN’ trial. CAPTAIN (A Comparison of TULSA Procedure vs. Radical ...
-
Study Suggests Futura’s Drug-Free Erectile Dysfunction Gel Suitable For US OTC Pathway
Futura article in HBW: Study Suggests Futura’s Drug-Free Erectile Dysfunction Gel Suitable For US OTC ...
-
Leonhardt’s Launchpads Accelerator to Showcase Eight Innovation Assets and Startups At 2022 Demo Day
Irvine, Calif., Nov. 16th, 2021 /PRDistribution/ — Leonhardt’s Launchpads announced today that they will showcase eight graduates of their innovation and startup launch accelerator program on a Demo Day. The event will occur both in person and virtually on Friday, January 14, 2022, at 3 pm PT at UCI Research Park, University Lab Partners, 5270 California Avenue, Suite 300, Irvine, CA ...
-
Alume Biosciences Granted FDA Fast Track Designation of ALM-488 for Surgical Nerve Visualization
Alume Biosciences, Inc., a clinical stage biotechnology company developing nerve-targeted pharmaceuticals for surgical and therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its lead compound ALM-488. ALM-488 is an investigational fluorescently labelled nerve targeting pharmaceutical being developed as an adjunct for the ...
-
S1 Biopharma Ceo Nick Sitchon To Participate In Maxim Group Llc Review Of Late Stage Innovations In Women’S Health
NEW YORK, March 2, 2021 /PRNewswire/ — S1 Biopharma, Inc. (S1), a clinical stage company advancing therapies based on central nervous system targets mediating sexual response, today announced that company CEO Nick Sitchon will participate in a panel discussion on late stage innovations in women’s health sponsored by Maxim Group LLC. The virtual program, part of the M-Vest Virtual ...
-
Concept Medical is Granted CE Certification for Sirolimus Coated MagicTouch Group of Products.
Concept Medical B.V. with its headquarters in Tampa, Florida has announced that on 16th October 2019, they have received the CE certification for their MagicTouch group of products. The CE certified products/brands are as listed below: MagicTouch – PTA (Sirolimus Coated PTA Balloon Catheter) for peripheral arterial disease MagicTouch – ED (Sirolimus Coated Balloon Catheter) for ...
-
Howard Leonhardt and Alex Richardson of Second Heart Assist discuss regenerating hearts and novel medical devices
During their recent visit to Victoria BC for lab testing services, Second Heart Assist Chairman and CEO, Howard Leonhardt (HL), and VP of Engineering & Product Development, Alex Richardson (AR), spoke with ViVitro Lab and Interim General Manager, Rob Fraser (RF), about their work at Second Heart Assist, and Leonhardt Ventures. RF: You both have a long history with medical devices. Please ...
-
Tissue Genesis LLC, and Human Life CORD Japan, Inc., Announce Exclusive Agreement to Advance Adult Stem Cell Therapies in Asia
Human Life CORD Japan, Inc., (HLC) a group company of Nihon Trim (Cord No. 6788, Tokyo Stock Exchange 1st Section) is pleased to announce a strategic agreement with Tissue Genesis, LLC (TG) to distribute its proprietary stem cell processing products in commercial clinics, research institutions, and hospitals in Japan and China. The 10-year agreement marks a major leap forward in advancing the ...
-
C4 Imaging Announces an Additional FDA 510(k) Clearance for its Positive-Signal MRI Marker - Sirius
C4 Imaging LLC is pleased to announce an additional US Food and Drug Administration 510(k) clearance for its Sirius MRI Marker, a novel positive-signal MRI Marker that is used during the treatment of prostate cancer with brachytherapy. This additional 510(k) clears Sirius MRI Markers to be sterilized with ethylene oxide. Previously only gamma sterilization was available; the addition of ethylene ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you